Anti-proliferative and apoptosis-inducing activity of lycopene against three subtypes of human breast cancer cell lines

Cancer Science

Volumn 105, Issue 3, 2014, Pages 252-257

  Takeshima, Mikako ^a   Ono, Misaki ^a   Higuchi, Takako ^a   Chen, Chen ^a   Hara, Takayuki ^a   Nakano, Shuji ^a  

^a NAKAMURA GAKUEN UNIVERSITY   (Japan)

Author keywords

Apoptosis; Breast cancer; G0 G1 arrest; Lycopene; Triple negative

Indexed keywords

CYCLIN D1; ESTROGEN RECEPTOR; LYCOPENE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROGESTERONE RECEPTOR; PROTEIN BAX; PROTEIN BCL XL; PROTEIN P21;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION;

APOPTOSIS; BREAST CANCER; G0/G1 ARREST; LYCOPENE; TRIPLE-NEGATIVE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CAROTENOIDS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MCF-7 CELLS; POLY(ADP-RIBOSE) POLYMERASES; SIGNAL TRANSDUCTION;

EID: 84895558622     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12349     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011; 16(Suppl. 1): 1-11.
3. Thomson CA. Diet and breast cancer: understanding risks and benefits. Nutr Clin Pract 2012; 27: 636-50.
4. Aune D, Chan DS, Vieira AR et al. Fruits, vegetables and breast cancer risk: a systematic review and meta-analysis of prospective studies. Breast Cancer Res Treat 2012; 134: 479-93.
5. Masala G, Assedi M, Bendinelli B et al. Fruit and vegetables consumption and breast cancer risk: the EPIC Italy study. Breast Cancer Res Treat 2012; 132: 1127-36.
6. Fung TT, Hu FB, McCullough ML et al. Diet quality is associated with the risk of estrogen receptor-negative breast cancer in postmenopausal women. J Nutr 2006; 136: 466-72.
7. Olsen A, Tjonneland A, Thomsen BL et al. Fruits and vegetables intake differentially affects estrogen receptor negative and positive breast cancer incidence rates. J Nutr 2003; 133: 2342-7.
8. Jung S, Spiegelman D, Baglietto L et al. Fruit and vegetable intake and risk of breast cancer by hormone receptor status. J Natl Cancer Inst 2013; 105: 219-36.
9. Rao AV, Rao LG. Carotenoids and human health. Pharmacol Res 2007; 55: 207-16.
10. Tanaka T, Shnimizu M, Moriwaki H. Cancer chemoprevention by carotenoids. Molecules 2012; 17: 3202-42.
11. Zhang X, Spiegelman D, Baglietto L et al. Carotenoid intakes and risk of breast cancer defined by estrogen receptor and progesterone receptor status: a pooled analysis of 18 prospective cohort studies. Am J Clin Nutr 2012; 95: 713-25.
12. Eliassen AH, Hendrickson SJ, Brinton LA et al. Circulating carotenoids and risk of breast cancer: pooled analysis of eight prospective studies. J Natl Cancer Inst 2012; 104: 1905-16.
13. Gerster H. The potential role of lycopene for human health. J Am Coll Nutr 1997; 16: 109-26.
14. Wei MY, Giovannucci EL. Lycopene, tomato products, and prostate cancer incidence: a review and reassessment in the PSA screening era. J Oncol 2012; 2012: 271063.
15. Arab L, Steck-Scott S, Fleishauer AT. Lycopene and the lung. Exp Biol Med (Maywood) 2002; 227: 894-9.
16. Liu C, Russell RM. Nutrition and gastric cancer risk: an update. Nutr Rev 2008; 66: 237-49.
17. Sharoni Y, Giron E, Rise M, Levy J. Effects of lycopene-enriched tomato oleoresin on 7, 12-dimethyl-benz[a]anthracene-induced rat mammary tumors. Cancer Detect Prev 1997; 21: 118-23.
18. Narisawa T, Fukaura Y, Hasebe M et al. Prevention of N-methylnitrosourea-induced colon carcinogenesis in F344 rats by lycopene and tomato juice rich in lycopene. Jpn J Cancer Res 1998; 89: 1003-8.
19. Kim DJ, Takasuka N, Kim JM et al. Chemoprevention by lycopene of mouse lung neoplasia after combined initiation treatment with DEN, MNU and DMH. Cancer Lett 1997; 120: 15-22.
20. Kelkel M, Schumacher M, Dicato M, Diederich M. Antioxidant and anti-proliferative properties of lycopene. Free Radic Res 2011; 45: 925-40.
21. Levy J, Bosin E, Feldman B et al. Lycopene is a more potent inhibitor of human cancer cell proliferation than either alpha-carotene or beta-carotene. Nutr Cancer 1995; 24: 257-66.
22. Tang FY, Shih CJ, Cheng LH, Ho HJ, Chen HJ. Lycopene inhibits growth of human colon cancer cells via suppression of the Akt signaling pathway. Mol Nutr Food Res 2008; 52: 646-54.
23. Ivanov NI, Cowell SP, Brown P et al. Lycopene differentially induces quiescence and apoptosis in androgen-responsive and -independent prostate cancer cell lines. Clin Nutr 2007; 26: 252-63.
24. Hantz HL, Young LF, Martin KR. Physiologically attainable concentrations of lycopene induce mitochondrial apoptosis in LNCaP human prostate cancer cells. Exp Biol Med (Maywood) 2005; 230: 171-9.
25. Nahum A, Hirsch K, Danilenko M et al. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes. Oncogene 2001; 20: 3428-36.
26. Karas M, Amir H, Fishman D et al. Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr Cancer 2000; 36: 101-11.
27. Teodoro AJ, Oliveira FL, Martins NB et al. Effect of lycopene on cell viability and cell cycle progression in human cancer cell lines. Cancer Cell Int 2012; 12: 36.
28. Neve RM, Chin K, Fridlyand J et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-27.
29. Stahl W, Sundquist AR, Hanusch M, Schwarz W, Sies H. Separation of beta-carotene and lycopene geometrical isomers in biological samples. Clin Chem 1993; 39: 810-4.
30. Ono M, Higuchi T, Takeshima M, Chen C, Nakano S. Differential anti-tumor activities of curcumin against Ras- and Src-activated human adenocarcinoma cells. Biochem Biophys Res Commun 2013; 436: 186-91.
31. Mayne ST, Cartmel B, Silva F et al. Plasma lycopene concentrations in humans are determined by lycopene intake, plasma cholesterol concentrations and selected demographic factors. J Nutr 1999; 129: 849-54.
32. Ansari MS, Gupta NP. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. Urol Oncol 2004; 22: 415-20.
33. Jatoi A, Burch P, Hillman D et al. A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. Urology 2007; 69: 289-94.
34. Vaishampayan U, Hussain M, Banerjee M et al. Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer 2007; 59: 1-7.
35. Ono M, Koga T, Ueo H, Nakano S. Effects of dietary genistein on hormone-dependent rat mammary carcinogenesis induced by ethyl methanesulphonate. Nutr Cancer 2012; 64: 1204-10.
36. Meloche S, Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007; 26: 3227-39.
37. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003; 3: 371-7.
38. Palozza P, Colangelo M, Simone R et al. Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines. Carcinogenesis 2010; 31: 1813-21.